Paclitaxel

The optimal dose and schedule of paclitaxel is not yet defined and is the subject of a number of clinical trials. These studies have not shown a clear-cut dose-response relationship. Trials evaluating administration schedule have not found either 24 h or 96 h infusion to be superior to 3 h infusion....

Full description

Saved in:

Bibliographic Details
Published in:	Gan to kagaku ryoho Vol. 28; no. 10; p. 1357
Main Authors:	Omuro, Y, Sasaki, T
Format:	Journal Article
Language:	Japanese
Published:	Japan 01-10-2001
Subjects:	Antineoplastic Agents, Phytogenic - administration & dosage Breast Neoplasms - drug therapy Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Dose-Response Relationship, Drug Drug Administration Schedule Female Humans Paclitaxel - administration & dosage
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The optimal dose and schedule of paclitaxel is not yet defined and is the subject of a number of clinical trials. These studies have not shown a clear-cut dose-response relationship. Trials evaluating administration schedule have not found either 24 h or 96 h infusion to be superior to 3 h infusion. These clinical evidence suggests that optimal dose and schedule of single-agent paclitaxel is 175 mg/m2 over 3 h. Weekly moderate-dose paclitaxel administration is generating much interest, as dose dense therapy, with very modest myelosuppression.
ISSN:	0385-0684